Compare
Precigen, Inc. vs Prothena Corp Public Ltd Co vs Janux Therapeutics, Inc. vs Zenas BioPharma, Inc.
| Latest fiscal year | Precigen, Inc. PGEN | Prothena Corp Public Ltd Co PRTA | Janux Therapeutics, Inc. JANX | Zenas BioPharma, Inc. ZBIO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $9.68M | $9.68M | $10.00M | $10.00M |
| Revenue growth (YoY) | +146.7% | -92.8% | -5.6% | +100.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$250.64M | -$244.09M | -$113.62M | -$377.74M |
| EPS (Diluted) | -$1.37 | -$4.53 | -$1.83 | -$8.44 |
| Operating cash flow | -$87.83M | -$163.58M | -$82.23M | -$172.33M |
| Free cash flow | -$89.83M | n/a | -$83.28M | -$172.35M |
| Cash & equivalents | $30.23M | $307.53M | $52.33M | $110.64M |
| Total assets | $155.50M | $326.80M | $1.00B | $383.64M |
| Total liabilities | $134.59M | $46.33M | $44.74M | $141.50M |
| Shareholders' equity | $20.91M | $280.47M | $956.82M | $242.14M |
| Return on year-end equity | n/m | -87.0% | -11.9% | -156.0% |
| Shares outstanding | 353.91M | 53.83M | 60.38M | 54.49M |
Revenue, most recent five fiscal years
| Fiscal year | Precigen, Inc. | Prothena Corp Public Ltd Co | Janux Therapeutics, Inc. | Zenas BioPharma, Inc. |
|---|---|---|---|---|
| Latest | $9.68M Ended 2025-12-31 | $9.68M Ended 2025-12-31 | $10.00M Ended 2025-12-31 | $10.00M Ended 2025-12-31 |
| 1 year earlier | $3.92M Ended 2024-12-31 | $135.16M Ended 2024-12-31 | $10.59M Ended 2024-12-31 | $5.00M Ended 2024-12-31 |
| 2 years earlier | $6.22M Ended 2023-12-31 | $91.37M Ended 2023-12-31 | $8.08M Ended 2023-12-31 | $50.00M Ended 2023-12-31 |
| 3 years earlier | $26.91M Ended 2022-12-31 | $53.91M Ended 2022-12-31 | $8.61M Ended 2022-12-31 | n/a |
| 4 years earlier | $14.27M Ended 2021-12-31 | $200.58M Ended 2021-12-31 | $3.64M Ended 2021-12-31 | n/a |